Delphi Diagnostics™ Inc and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of Delphi’s Proprietary Test, SET2,3™, into the Adaptive Randomization Process for the Ongoing I-SPY 2 TRIAL™
Press Release Delphi Diagnostics™ Inc and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of Delphi’s Proprietary Test, SET2,3™, into the Adaptive Randomization Process for the Ongoing I-SPY 2 TRIAL™ Houston, TX, October 27, 2022 – Delphi Diagnostics, Inc and Quantum Leap Healthcare Collaborative™ (QLHC) announce the inclusion of Delphi’s SET2,3TM test for use in the I-SPY 2 […]
SET2,3TM index adds independent, complementary information to personalize breast cancer treatment
Press Release SET2,3™ Index Adds Independent, Complementary Information to Personalize Breast Cancer Treatment December 14, 2021 – Delphi Diagnostics Inc. is pleased to announce that its SET2,3 index, a standard measure of gene expression known as the Sensitivity-to-Endocrine-Therapy, was found to have prognostic value that complements the known prognostic value of the 21-gene Oncotype DX […]
SET2,3 Results Can Determine Prognosis and Prediction of Benefit from Dose-Dense Chemotherapy in Estrogen Receptor-Positive (ER+) Breast Cancer Presented at ASCO 2022
Press Release SET2,3™ Results Can Determine Prognosis and Prediction of Benefit from Dose-Dense Chemotherapy in Estrogen Receptor-Positive (ER+) Breast Cancer Presented at ASCO 2022 For patients diagnosed with ER+ breast cancer and low endocrine sensitivity (a Low SET2,3 index), dose-dense chemotherapy was associated with superior disease-free survival (DFS) and overall survival (OS) outcomes when compared […]
Delphi Diagnostics™ Inc. Announced the Issuance of a New U.S. Patent Covering the Sensitivity to Endocrine Therapy (SETER/PR) Test Through 2037
Press Release Delphi Diagnostics™ Inc. Announced the Issuance of a New U.S. Patent Covering the Sensitivity to Endocrine Therapy (SETER/PR) Test Through 2037 Patents recently issued in the US and allowed in Japan provide additional coverage for the company’s proprietary SETTM technologies for patients with HR+HER2- breast cancer and strengthens the company’s intellectual property portfolio. Houston, […]
Delphi Diagnostics™ Inc Announces a Publication Showing that the Sensitivity-to-Endocrine-Therapy (SET2,3) Index had Prognostic Value that was Independent and Complementary to the 21-gene Recurrence Score (Oncotype DX Breast Recurrence Score®) in Node-Positive Breast Cancer
Press Release Delphi Diagnostics™ Inc Announces a Publication Showing that the Sensitivity-to-Endocrine-Therapy (SET2,3) Index had Prognostic Value that was Independent and Complementary to the 21-gene Recurrence Score (Oncotype DX Breast Recurrence Score®) in Node-Positive Breast Cancer Published in the Journal of Clinical Oncology, SET2,3, and Recurrence Score were independent of each other and provided additive […]
Two Abstracts Highlighting the Endocrine Activity Index were Presented at the 2024 Annual Society of Clinical Oncology Meeting
Press Release Two Abstracts Highlighting the Endocrine Activity Index were Presented at the 2024 Annual Society of Clinical Oncology Meeting Abstracts highlighting the value of the Endocrine Activity Index were presented at ASCO 2024. The first abstract (538) highlighted the prognostic value for patients with Stage II-III breast cancer. The second abstract (565) highlighted the […]
New Data Confirms Endocrine Activity Index® as a Predictor of Benefit from Dose-Dense Chemotherapy
Press Release New Data Confirms Endocrine Activity Index as a Predictor of Benefit from Dose-Dense Chemotherapy Data from the GEICAM/9906 trial, presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2024, provides independent confirmation of the predictive value of the Endocrine Activity Index (EAITM).1 In addition, results from a 12-year outcomes analysis from the […]